Anchor Capital Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 199,497 shares of the company’s stock after selling 5,244 shares during the period. Anchor Capital Advisors LLC’s holdings in Johnson & Johnson were worth $26,391,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in JNJ. State Street Corp increased its holdings in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Johnson & Johnson by 3.7% during the second quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after buying an additional 405,517 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Johnson & Johnson by 1.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock worth $1,388,775,000 after buying an additional 201,703 shares during the last quarter. Clearbridge Investments LLC increased its holdings in Johnson & Johnson by 3.4% during the first quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after buying an additional 310,831 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Johnson & Johnson by 0.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after buying an additional 42,144 shares during the last quarter. Institutional investors own 65.93% of the company’s stock.

JNJ has been the subject of several recent research reports. UBS AG reiterated a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 target price for the company in a research note on Thursday, July 27th. Cowen and Company set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Thursday, August 24th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, September 1st. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $143.70.

COPYRIGHT VIOLATION NOTICE: This article was published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/11/13/anchor-capital-advisors-llc-has-26-39-million-stake-in-johnson-johnson-jnj.html.

Shares of Johnson & Johnson (NYSE JNJ) opened at $139.56 on Monday. Johnson & Johnson has a 1 year low of $109.32 and a 1 year high of $144.35. The stock has a market cap of $374,930.72, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same period in the previous year, the business posted $1.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 10.3% on a year-over-year basis. equities research analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.41%. Johnson & Johnson’s payout ratio is presently 58.33%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.